Karen Finn reviews the main events in the field of international pharmaceutical regulatory affairs over the past year.
The divide between premarket and postmarket regulation of pharmaceuticals has officially been relegated to the archives. In 2008, much of regulators’ activity focused on implementing this shift in approach, especially with respect to safety...
Please login to read the full article.
